期刊文献+

反相高效液相色谱法测定人血浆中伊洛哌酮的含量

Determination of iloperidone in human plasma by RP-HPLC
原文传递
导出
摘要 目的建立反相高效液相色谱(RP-HPLC)法测定人体血浆中伊洛哌酮的含量。方法色谱柱为美国Diamonsil(?)C_(18)反相柱(250mm×4.6mm,5μm),流动相为乙腈-甲醇-缓冲液(40:55:5,V/V/V),流速为1.0 mL·min^(-1),柱温35℃,检测波长280 nm。结果伊洛哌酮血浆质量浓度在0.021~2.688 mg·L^(-1)范围内线性关系良好(r=0.998 9),平均相对回收率为98.21%,平均日间精密度为6.02%。结论本法快速、简便、准确,适于伊洛哌酮药动学研究和临床监测。 AIM To establish a RP-HPLC method for content determination of iloperidone in human plasma. METHODS A Diamonsil C_18 column (250 mm×4.6 ram, 5 μm) was used with mobile phase of acetonitrile- methanol-buffer (40 : 55 : 5, V/V/V) . Flow rate was 1.0 mL'min-1, column temperature was 35 ℃. UV detection wavelength was 280 nm. RESULTS Within a mass concentration range of 0.021 - 2.688 mg·L-1, Standard curve of iloperidone had a good linearity (r = 0.998 9). The average relative recovery was 98.21%, and the average daytime precision was 6.02%. CONCLUSION This method is rapid, convenient and accurate. It can be used for the pharmacokinetics study and clinical monitor of iloperidone.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2013年第9期731-734,共4页 Chinese Journal of New Drugs and Clinical Remedies
基金 河南省卫生厅卫生科技创新型人才工程项目(20103052)
关键词 伊洛哌酮 色谱法 高压液相 血浆 含量 iloperidone chromatography, high pressure liquid plasma content
  • 相关文献

参考文献9

  • 1CITROME L. lloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second- generation antipsychotic[J], lnt J Clin Pract, 2009, 63(8): 1237- 1248.
  • 2CITROME L, MENG X, HOCHFELD M. Efficacy of iloperidone in schizophrenia: A PANSS five-factor analysis[J]. Schizophr Res, 2011, 131(1-3): 75-81.
  • 3常麦会,李乐华.新型抗精神病药伊潘立酮的研究进展[J].中南药学,2010,8(11):858-862. 被引量:5
  • 4CRABTREE BL, MONTGOMERY J. lloperidone for the mana- gement of adults with schizophrenia [J]. Clin Ther, 2011, 33(3 ) : 330-345.
  • 5CITROME L, MENG X, HOCHFELD M, et al. Efllcacy of iloperidone in the short-term treatment of schizophrenia: a posthoc analysis of pooled patient data from four phase Ill , placebo and active controlled trials[J]. Hum Psychopharmacol, 2012, 27 (l): 24-32.
  • 6MUTLIB AE, KLEIN JT. Application of liquid chromatography/ mass spectrometry in accelerating |he identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone[J]. J Pharmacol Exp Ther, 1998, 286 (3): 1285- 1293.
  • 7王来海,张红星,张瑞岭.新型非典型抗精神病药:伊洛哌酮[J].中国新药与临床杂志,2010,29(9):716-718. 被引量:2
  • 8MUTLIB AE, STRUPCZEWSKI JT. Application of hyphenated LC/NMR and LC/MS techniques in rapid identification of in 1'itro and in vivo metabolites of iloperidone[J]. Drug Metab and Dispos, 1995, 23(9): 951-964.
  • 9KANE JM, LAURIELLO J, LASKA E, et td. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for tile treatment of schizophrenia[J]. J Clit Psyehopharmacol, 2008, 28 (2) : S29-S40.

二级参考文献38

  • 1CACCIA S, PASINA L, NOBILI A. New atypical antipsychotics for schizophrenia: iloperidone[J]. Drug Des Devel Ther, 2010, 18(4) : 33-48.
  • 2CITROME L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second- generation antipsychotic[J]. Int J Clin Pract, 2009, 63 (8): 1237 - 1248.
  • 3CUTLER AJ. Iloperidone: a new option for the treatment of schizophrenia[J]. Expert Rev Neurother, 2009, 9(12): 1727- 1741.
  • 4MARINO J, CABALLERO J. Iloperidone for the treatment of schizophrenia[J]. Ann Pharmacother, 2010, 44(5): 863-870.
  • 5BISHARA D, TAYLOR. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability[J]. Drugs, 2008, 68 (16) : 2269-2292.
  • 6CITROME L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commereialised second- generation antipsychntic [J]. Int J Clin Pract, 2009, 3 (8): 1237-1248.
  • 7ALBERS LJ, MUSENGA A, RAGGI MA. Iloperidone: a new benzisoxazole atypical andpsychotic drug. Is it novel enough to impact the crowded atypical antipsyehatie market? [J]. Expert Opin Investig Drugs, 2008, 17( 1 ) : 61-75.
  • 8KANE JM, LAURIELLO J, LASKA E, et al. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia[J]. J Clin Psychopharmacol, 2008, 28 (2 Suppl 1) : S29-S35.
  • 9CUTLER AJ, KALALI AH, WEIDEN PJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia [J]. J Clin Psychopharmacol, 2008, 28(2 Suppl 1): S20-S28.
  • 10POTKIN SG, LITMAN RE, TORRES R, et al. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies[J]. J Clin Psychopharmacol, 2008, 28(2 Suppl 1) : S4-S11.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部